Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Lonard

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Cancer Research|January 7, 2014
Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1Ying Wang, David M Lonard, Yang Yu, et al.
Journal of Cell Science|November 19, 2010
REGgamma modulates p53 activity by regulating its cellular localizationJian Liu, Guowu Yu, Yanyan Zhao, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 6, 2013
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnoverChuandong Geng, Bin He, Limei Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 24, 2020
A steroid receptor coactivator stimulator (MCB-613) attenuates adverse remodeling after myocardial infarctionLisa K Mullany, Aarti D Rohira, John P Leach, et al.
Molecular Cell|July 16, 2013
Proteomic analysis of coregulators bound to ERα on DNA and nucleosomes reveals coregulator dynamicsCharles E Foulds, Qin Feng, Chen Ding, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
MCB-613 exploits a collateral sensitivity in drug resistant <i>EGFR</i>-mutant non-small cell lung cancer through covalent inhibition of KEAP1Christopher F Bassil, Gray R Anderson, Benjamin Mayro, et al.
Nature Communications|August 9, 2020
The REGγ inhibitor NIP30 increases sensitivity to chemotherapy in p53-deficient tumor cellsXiao Gao, Qingwei Wang, Ying Wang, et al.
Nature Communications|September 24, 2020
Author Correction: The REGγ inhibitor NIP30 increases sensitivity to chemotherapy in p53-deficient tumor cellsXiao Gao, Qingwei Wang, Ying Wang, et al.
Oncogene|May 12, 2018
Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targetsLeah A Gates, Guowei Gu, Yue Chen, et al.
Nature Communications|January 14, 2026
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridgeChristopher F Bassil, Kerry Dillon, Gray R Anderson, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Cancer Research|January 7, 2014
Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1Ying Wang, David M Lonard, Yang Yu, et al.
Journal of Cell Science|November 19, 2010
REGgamma modulates p53 activity by regulating its cellular localizationJian Liu, Guowu Yu, Yanyan Zhao, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 6, 2013
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnoverChuandong Geng, Bin He, Limei Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 24, 2020
A steroid receptor coactivator stimulator (MCB-613) attenuates adverse remodeling after myocardial infarctionLisa K Mullany, Aarti D Rohira, John P Leach, et al.
Molecular Cell|July 16, 2013
Proteomic analysis of coregulators bound to ERα on DNA and nucleosomes reveals coregulator dynamicsCharles E Foulds, Qin Feng, Chen Ding, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
MCB-613 exploits a collateral sensitivity in drug resistant <i>EGFR</i>-mutant non-small cell lung cancer through covalent inhibition of KEAP1Christopher F Bassil, Gray R Anderson, Benjamin Mayro, et al.
Nature Communications|August 9, 2020
The REGγ inhibitor NIP30 increases sensitivity to chemotherapy in p53-deficient tumor cellsXiao Gao, Qingwei Wang, Ying Wang, et al.
Nature Communications|September 24, 2020
Author Correction: The REGγ inhibitor NIP30 increases sensitivity to chemotherapy in p53-deficient tumor cellsXiao Gao, Qingwei Wang, Ying Wang, et al.
Oncogene|May 12, 2018
Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targetsLeah A Gates, Guowei Gu, Yue Chen, et al.
Nature Communications|January 14, 2026
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridgeChristopher F Bassil, Kerry Dillon, Gray R Anderson, et al.
Pageof 9